- Previous Close
0.6450 - Open
0.6400 - Bid 0.6350 x --
- Ask 0.6600 x --
- Day's Range
0.6350 - 0.6400 - 52 Week Range
0.4200 - 0.8500 - Volume
9,753 - Avg. Volume
92,401 - Market Cap (intraday)
144.233M - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.10
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
www.geneticsignatures.comRecent News: GSS.AX
View MorePerformance Overview: GSS.AX
Trailing total returns as of 1/8/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSS.AX
View MoreValuation Measures
Market Cap
144.23M
Enterprise Value
109.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.75
Price/Book (mrq)
2.36
Enterprise Value/Revenue
11.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-129.74%
Return on Assets (ttm)
-19.69%
Return on Equity (ttm)
-34.34%
Revenue (ttm)
13.77M
Net Income Avi to Common (ttm)
-17.86M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
36.25M
Total Debt/Equity (mrq)
2.00%
Levered Free Cash Flow (ttm)
-10.88M